Biogen’s IMRALDI®, an adalimumab biosimilar candidate, granted positive opinion by CHMP
The CHMP of the EMA has issued a positive opinion for IMRALDI®, an adalimumab biosimilar candidate referencing Humira®. MRALDI marks the third anti-TNF candidate to be submitted to the EMA by Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen. June 23, 2017